ArticleCancer cell2017
Molecular Landscape of Non-Muscle Invasive Bladder Cancer.
Article in Cancer cell, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Rapamycin Prevents Surgery-Induced Immune Dysfunction in Patients with Bladder Cancer.Cancer immunology research · 2019Trial
- The ZIF-8 nanoplatform targeted delivery of IFI44 siRNA to suppress bladder cancer development via modulating the PI3K/AKT signaling pathway.Journal of nanobiotechnology · 2026Article
- Molecular profiling of bladder cancer xenografts defines relevant molecular subtypes and provides a resource for biomarker discovery.Translational oncology · 2025Article
- Prognostic value and immune landscapes of disulfidptosis‑related lncRNAs in bladder cancer.Molecular and clinical oncology · 2025Article
- Actin-related protein 2/3 complex subunit 1B promotes ovarian cancer progression by regulating the AKT/PI3K/mTOR signaling pathway.Journal of translational internal medicine · 2024Article
- Somatic Mutation of the Non-Muscle-Invasive Bladder Cancer Associated with Early Recurrence.Diagnostics (Basel, Switzerland) · 2023Article
- Kavalactone Kawain Impedes Urothelial Tumorigenesis in UPII-Mutant Ha-Ras Mice via Inhibition of mTOR Signaling and Alteration of Cancer Metabolism.Molecules (Basel, Switzerland) · 2023Article
- Epigenetic regulation ofMolecular therapy. Nucleic acids · 2022Article
- Immune status for monitoring and treatment of bladder cancer.Frontiers in immunology · 2022Review
- Immunotherapy in non-muscle-invasive bladder cancer: current status and future directions.World journal of urology · 2021Review
- Narrative review: update on immunotherapy and pathological features in patients with bladder cancer.Translational andrology and urology · 2021Review
- Article
- Article
- Genomic classification and risk stratification of bladder cancer.World journal of urology · 2019Review
- Comprehensive Gene Expression Analysis in NMIBC Using RNA-seq Reveals New Therapy Strategies.Frontiers in oncology · 2019Article
- Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
Abstract
In this issue of Cancer Cell, Hurst et al. report an integrated analysis of non-invasive (stage Ta) bladder cancer. Two genomic subtypes are distinguished by chromosome 9q loss, resulting in increased AKT/PI3K/mTOR signaling. Tumors from female patients have a higher frequency of KDM6A mutations.
Indexed as
Identifiers
29136502What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.